{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/9969517enq4",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1038/ncomms14207",
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1002/dad2.12391",
    "https://doi.org/10.1234/abcd1234"
  ],
  "dcterms:references": [
    "# Noradrenergic Regulation of DOPAL Production: A Compensatory Anti-Amyloidogenic Mechanism in Early Alzheimer's Disease\n\n## 1. Background\nDOPAL (3,4-dihydroxyphenylacetaldehyde) is a reactive dopamine metabolite produced by monoamine oxidase (MAO) that unexpectedly demonstrates neuroprotective properties by decreasing Aβ oligomerization in human neuroblastoma cells. In Alzheimer's disease (AD) models like Tg2576 mice, dopaminergic neurons in the ventral tegmental area (VTA) selectively degenerate during pre-plaque stages, reducing dopamine release in the hippocampus, while noradrenergic projections from the locus coeruleus (LC) remain intact, as evidenced by preserved hippocampal noradrenaline outflow. Previous research has shown that L-DOPA administration in AD models decreases Aβ plaque burden by upregulating Aβ-degrading enzymes like neprilysin (NEP) and ADAM17, suggesting complex interactions between catecholamine systems and amyloid pathology.\n\n## 2. Knowledge Gap\nWhile both DOPAL's anti-amyloidogenic properties and the preservation of noradrenergic transmission in early AD have been separately documented, the potential functional relationship between these phenomena remains unexplored. Specifically, it is unknown whether noradrenergic signaling modulates the production of DOPAL in a compensatory manner to mitigate Aβ oligomerization when dopaminergic function begins to decline.\n\n## 3. Central Hypothesis\nPreserved noradrenergic projections in early Alzheimer's disease promote the conversion of residual dopamine to DOPAL through adrenergic receptor-mediated enhancement of monoamine oxidase activity in non-dopaminergic cells, creating a compensatory anti-amyloidogenic mechanism that delays Aβ aggregation and associated neurotoxicity.\n\n## 4. Proposed Mechanism\n1. As dopaminergic neurons in the VTA begin to degenerate in early AD, noradrenaline released from preserved LC projections activates β-adrenergic receptors on neighboring neurons and glial cells in the hippocampus and other affected brain regions.\n2. β-adrenergic receptor activation increases intracellular cAMP levels, which enhances MAO-B expression and activity through PKA-dependent phosphorylation and transcriptional regulation.\n3. This enhanced MAO-B activity in non-dopaminergic cells more efficiently converts the diminishing supply of dopamine to DOPAL, maintaining DOPAL at levels sufficient to interact with Aβ monomers.\n4. DOPAL binds to specific regions of Aβ peptides, inducing conformational changes that prevent β-sheet formation and subsequent oligomerization, while simultaneously increasing Aβ susceptibility to degradation by enzymes like NEP and ADAM17.\n5. This noradrenergic-mediated enhancement of DOPAL production serves as a compensatory neuroprotective mechanism during early disease stages, which eventually fails as noradrenergic neurons also degenerate in later AD progression.\n\n## 5. Testable Predictions\n1. Pharmacological blockade of β-adrenergic receptors in young Tg2576 mice should decrease MAO-B activity, reduce DOPAL/dopamine ratios, and accelerate Aβ oligomerization and plaque formation compared to untreated controls.\n2. Chemical lesioning of noradrenergic neurons (using DSP-4 or similar compounds) in pre-symptomatic AD model mice should decrease hippocampal DOPAL levels and increase the ratio of oligomeric to monomeric Aβ, an effect that could be rescued by direct DOPAL administration.\n3. Microdialysis samples from the hippocampus of aging Tg2576 mice should show a positive correlation between noradrenaline levels and DOPAL/dopamine ratios, which should inversely correlate with local Aβ oligomer concentrations before significant plaque deposition occurs.\n\n## 6. Potential Experimental Approaches\n1. Develop a primary neuronal-glial co-culture system from AD model mice to investigate how noradrenergic stimulation (via β-adrenergic agonists) affects MAO-B activity, DOPAL production, and Aβ oligomerization. Use specific inhibitors of adrenergic receptors, MAO-B, and ALDH to dissect the proposed pathway, while measuring DOPAL levels via HPLC and Aβ oligomerization through immunoblotting and ThT fluorescence.\n\n2. Generate a transgenic mouse with cell-type-specific expression of a DOPAL biosensor crossed with Tg2576 mice to visualize and quantify DOPAL production in vivo before and after pharmacological manipulation of noradrenergic transmission. Combine with immunohistochemistry for Aβ oligomers and plaques to establish spatial and temporal relationships between DOPAL levels and amyloid pathology progression after noradrenergic system manipulation.\n\nThis hypothesis provides a novel perspective on how preserved noradrenergic function might serve as an endogenous compensatory mechanism in early Alzheimer's disease, potentially explaining why treatments that enhance catecholamine levels (like L-DOPA) demonstrate therapeutic benefits in AD models. Furthermore, it suggests that strategies aimed at enhancing this DOPAL-mediated protection could represent a new therapeutic avenue for early intervention in AD."
  ],
  "dcterms:subject": [
    "amyloid beta",
    "Brain"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "Noradrenaline outflow in the hippocampus did not differ between wild-type and Tg2576 mice at 6 months of age, suggesting preserved noradrenergic projections from the locus coeruleus."
  ],
  "dcterms:abstract": [
    "The study examines dopaminergic neuron loss in Alzheimers disease focusing on the ventral tegmental area VTA in Tg2576 mice The research demonstrates selective loss of dopaminergic neurons specifically in the VTA during pre plaque stages contrasting with Parkinsons disease where neurons are lost in the substantia nigra pars compacta but preserved in VTA Apoptotic cell death contributes to VTA dopaminergic neuron degeneration affecting dopamine release in the hippocampus and impacting synaptic plasticity particularly in the hippocampal CA1 region Reduced dopamine outflow in Tg2576 mice leads to memory deficits and impaired reward processing while noradrenaline outflow remains unchanged indicating preserved noradrenergic projections from the locus coeruleus The study investigated several treatments Levodopa L DOPA administration successfully rescued multiple deficits including CA1 synaptic plasticity dendritic spine density hippocampal post synaptic density composition memory function and food reward processing L DOPA was administered at 10 mg kg along with benserazide at 12 mg kg Similarly selegiline a monoamine oxidase B inhibitor improved dopamine outflow in the hippocampus restored synaptic plasticity dendritic spine density memory performance and reward processing The treatment also restored D1 receptors and GluA1 expression in hippocampal PSD fractions These findings establish a clear link between dopamine signaling memory formation and reward processing in Alzheimers disease with dopaminergic dysfunction occurring at early stages The research suggests potential therapeutic approaches through dopamine system modulation using established drugs like L DOPA and selegiline",
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings.",
    "Background: One of the most severe consequences of ageing is cognitive decline, which is associated with dysfunction of the brain microvasculature. Thus, repairing the brain vasculature could result in healthier brain function. Methods: To better understand the potential beneficial effect of endothelial progenitor cells (EPCs) in vascular repair, we studied the adhesion and integration of EPCs using the early embryonic mouse aorta–gonad–mesonephros – MAgEC 10.5 endothelial cell line. Results: Combination of progenitor cell therapy with senolytic therapy and prior activation of EPCs are promising for improving EPC adhesion and integration into the cerebral vasculature.",
    "Alzheimer’s disease (AD) is a neurodegenerative illness with a typical age of onset exceeding 65 years of age. The age dependency of the condition led us to track the appearance of DNA damage in the frontal cortex of individuals who died with a diagnosis of AD. The connection between aging and the loss of genomic integrity is compelling because DNA damage has also been identified as a possible cause of cellular senescence. This study investigates the distribution of DNA damage and senescence in the AD cortex."
  ]
}